NASDAQ:GPCR Structure Therapeutics (GPCR) Stock Price, News & Analysis $19.30 +0.16 (+0.84%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$18.90 -0.40 (-2.07%) As of 08/29/2025 05:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Structure Therapeutics Stock (NASDAQ:GPCR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Structure Therapeutics alerts:Sign Up Key Stats Today's Range$18.26▼$19.4150-Day Range$16.20▼$22.3852-Week Range$13.22▼$45.37Volume514,636 shsAverage Volume863,697 shsMarket Capitalization$1.11 billionP/E RatioN/ADividend YieldN/APrice Target$75.71Consensus RatingBuy Company Overview Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California. Read More Structure Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks56th Percentile Overall ScoreGPCR MarketRank™: Structure Therapeutics scored higher than 56% of companies evaluated by MarketBeat, and ranked 479th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingStructure Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageStructure Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Structure Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Structure Therapeutics are expected to grow in the coming year, from ($0.82) to ($0.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Structure Therapeutics is -18.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Structure Therapeutics is -18.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioStructure Therapeutics has a P/B Ratio of 1.44. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Structure Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted13.14% of the float of Structure Therapeutics has been sold short.Short Interest Ratio / Days to CoverStructure Therapeutics has a short interest ratio ("days to cover") of 8.9.Change versus previous monthShort interest in Structure Therapeutics has recently decreased by 8.52%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldStructure Therapeutics does not currently pay a dividend.Dividend GrowthStructure Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted13.14% of the float of Structure Therapeutics has been sold short.Short Interest Ratio / Days to CoverStructure Therapeutics has a short interest ratio ("days to cover") of 8.9.Change versus previous monthShort interest in Structure Therapeutics has recently decreased by 8.52%, indicating that investor sentiment is improving significantly. News and Social Media3.0 / 5News Sentiment1.42 News SentimentStructure Therapeutics has a news sentiment score of 1.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.05 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Structure Therapeutics this week, compared to 5 articles on an average week.Search InterestOnly 3 people have searched for GPCR on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Structure Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Structure Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.60% of the stock of Structure Therapeutics is held by insiders.Percentage Held by Institutions91.78% of the stock of Structure Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Structure Therapeutics' insider trading history. Receive GPCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Structure Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GPCR Stock News HeadlinesBrokerages Set Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Target Price at $75.71August 25, 2025 | americanbankingnews.comGuggenheim Lowers Structure Therapeutics (GPCR) PT to $90 Ahead of Key Clinical Trial DataAugust 18, 2025 | msn.comTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.August 30 at 2:00 AM | Porter & Company (Ad)Structure Therapeutics: Key Milestones Dead AheadAugust 17, 2025 | seekingalpha.comEli Lilly, Superluminal Medicines announce collaborationAugust 14, 2025 | msn.comCan Structure Therapeutics’ (GPCR) Aggressive Funding Moves Accelerate Its Obesity Drug Ambitions?August 13, 2025 | finance.yahoo.comStructure Therapeutics To Present Late-Breaking ADA Data on Oral Amylin Agonist ACCG-2671August 11, 2025 | msn.comStructure Therapeutics Reports Second Quarter 2025 Financial Results and Recent HighlightsAugust 6, 2025 | globenewswire.comSee More Headlines GPCR Stock Analysis - Frequently Asked Questions How have GPCR shares performed this year? Structure Therapeutics' stock was trading at $27.12 at the beginning of the year. Since then, GPCR stock has decreased by 28.8% and is now trading at $19.30. How were Structure Therapeutics' earnings last quarter? Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) announced its quarterly earnings data on Wednesday, August, 6th. The company reported ($0.36) earnings per share for the quarter, missing analysts' consensus estimates of ($0.28) by $0.08. When did Structure Therapeutics IPO? Structure Therapeutics (GPCR) raised $150 million in an initial public offering on Friday, February 3rd 2023. The company issued 10,740,000 shares at $13.00-$15.00 per share. Who are Structure Therapeutics' major shareholders? Structure Therapeutics' top institutional investors include Ameriprise Financial Inc. (2.76%), Vestal Point Capital LP (2.08%), Orbimed Advisors LLC (2.08%) and Franklin Resources Inc. (1.29%). How do I buy shares of Structure Therapeutics? Shares of GPCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Structure Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Structure Therapeutics investors own include Alamos Gold (AGI), Plug Power (PLUG), KALA BIO (KALA), Ovid Therapeutics (OVID), Comtech Telecommunications (CMTL), Fortress Biotech (FBIO) and Alto Ingredients (ALTO). Company Calendar Last Earnings8/06/2025Today8/30/2025Next Earnings (Estimated)11/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GPCR CIK1888886 Webwww.structuretx.com Phone628-229-9277FaxN/AEmployees136Year FoundedN/APrice Target and Rating Average Price Target for Structure Therapeutics$75.71 High Price Target$118.00 Low Price Target$50.00 Potential Upside/Downside+292.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($1.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$122.53 million Net MarginsN/A Pretax MarginN/A Return on Equity-21.31% Return on Assets-20.34% Debt Debt-to-Equity RatioN/A Current Ratio20.48 Quick Ratio20.48 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$13.40 per share Price / Book1.44Miscellaneous Outstanding Shares57,598,000Free Float54,373,000Market Cap$1.11 billion OptionableOptionable Beta-1.89 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:GPCR) was last updated on 8/30/2025 by MarketBeat.com Staff From Our Partners“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Structure Therapeutics Inc. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Structure Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.